Peposertib
Drug timelines are a Plus or Pro feature.
7 regulatory and trial events tracked for Peposertib, covering 2022-07-07 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors [Phase 1]